Abeona Therapeutics Inc. Registered Shares DL -,01
- BID
5.55
- ASK
5.788
- 2,031 Units3,455 Units
- 07/21, 10:17:50 AM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
1.93%
Market Cap
-
P/E Ratio
5.20
Dividend Yield
0.00 %
Earnings per Share
0.90 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 5.55 G | 0 Units |
| PRICE DETERMINATION TIME | 07/21/2026 / 10:17:50 AM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 5.558 | 5.548 |
| PREV. DAY'S PRICE | 5.59 | (07/20) |
| CHANGE DAY BEFORE | -0.04 | -0.72 % |
| 52 WEEK HIGH / LOW | 6.392 (07/15) | 3.56 (11/06) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | -2.34 | -1.44 | 0.90 | -0.64 | -0.18 |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | - | - |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | - | - | 5.20 | - | - |
PRICE - BOOK RATIO | 8.96 | 5.77 | 1.82 | - | - |
PRICE - SALES RATIO | 30.60 | - | 59.89 | - | - |
PRICE - CASH FLOW RATIO | - | - | - | - | - |
Master Data
| WKN | A3DMHM |
| ISIN | US00289Y2063 |
| SYMBOL | PCJ |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | ABEONA THERAPEUT. DL-,01 |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | - |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | - |
| MARKET CAPITALISATION | - |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | -9.49 % | 14.20 % | 20.47 % | 25.34 % | -1.93 % | 65.58 % | -78.31 % | 19.96 % |
| HIGH | 6.39 | 6.39 | 6.39 | 6.39 | 6.39 | 8.17 | 29.93 | 6.39 |
| LOW | 5.59 | 4.73 | 4.31 | 3.60 | 3.56 | 2.64 | 2.08 | 3.60 |
Dividende
pro Aktie
ABEONA THERAPEUT. DL-,01 does not deliver dividend information
Company profile
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.